Kevin Eggan, PhD, joined BioMarin Pharmaceutical Inc. in October 2020 as Group Vice President, Head of Research and Early Development and was recently promoted to Chief Scientific Officer, SVP, Head of Research and Early Development. Kevin is responsible for the execution of BioMarin’s discovery research programs, helping to shape the vision and longterm growth of our company through the oversight of an exceptional research pipeline of first- or best-in-class therapies. Prior to joining BioMarin, Kevin served as a tenured Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Director of Stem Cell Biology for the Stanley Center for Psychiatric Research at the Broad Institute, and an Institute Member of the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard. He has published 130 scientific articles and holds 13 patents. Kevin also received the MacArthur Foundation’s“GeniusGrant”and was named one of 50 Howard Hughes Medical Institute Early Career Scientists, among other distinctions. In addition, he has served on the Scientific Advisory Boards of Ipierian, Roche, and Angelini Pharma.